Abstract
Drugs for several diseases are still given without regard to the time of the day. Variation in dosing time is generally related with the effectiveness and toxicity of many drugs. On the other hand, several drugs affect the circadian clock. The knowledge of interactions between the circadian clock and drugs is valuable in clinical practice. The pharmacodynamics and pharmacokinetics of the medication influence the chronopharmacological phenomena and recent advances in it have made the traditional goal of pharmaceutics rather outdated. Enhanced progress in chronopharmacotherapy can be achieved if an identification of a rhythmic marker for selecting dosing time is done. However, technology involved in development of drug delivery systems (DDS) that match the circadian rhythm, and the unraveling of the relationship between circardian clock and pathology may be the hindrance in its prosperity for now. The Chronopharmaceutical Drug Delivery System (CDDS) has emerged during the last decade as a possible drug delivery system against several diseases, which may lead to the creation of a sub-disciple of pharmaceutics to be explored called ‘chronopharmaceutics’. The review addresses the approaches to this sub-discipline, call attention to potential disease-targets, identifies existing technologies, hurdles and future of chropharmaceuticals. Chronopharmaceuticals coupled with nanotechnology could be the future of DDS, and lead to safer and more efficient disease therapy in the future.
Keywords: Chronopharmaceuticals, models, circadian, chronopharmacokinetics, oscillation, endogenous, microfabrication, ulcers, osteoarthritis, asthma, hepatic, flourescent, polyelectrolyte gels, hyrophilic, hydrophobic, chronobiological, modelling
Current Pharmaceutical Design
Title: Chronopharmaceuticals: Hype or Future of Pharmaceutics
Volume: 17 Issue: 15
Author(s): Anil K. Philip and Betty Philip
Affiliation:
Keywords: Chronopharmaceuticals, models, circadian, chronopharmacokinetics, oscillation, endogenous, microfabrication, ulcers, osteoarthritis, asthma, hepatic, flourescent, polyelectrolyte gels, hyrophilic, hydrophobic, chronobiological, modelling
Abstract: Drugs for several diseases are still given without regard to the time of the day. Variation in dosing time is generally related with the effectiveness and toxicity of many drugs. On the other hand, several drugs affect the circadian clock. The knowledge of interactions between the circadian clock and drugs is valuable in clinical practice. The pharmacodynamics and pharmacokinetics of the medication influence the chronopharmacological phenomena and recent advances in it have made the traditional goal of pharmaceutics rather outdated. Enhanced progress in chronopharmacotherapy can be achieved if an identification of a rhythmic marker for selecting dosing time is done. However, technology involved in development of drug delivery systems (DDS) that match the circadian rhythm, and the unraveling of the relationship between circardian clock and pathology may be the hindrance in its prosperity for now. The Chronopharmaceutical Drug Delivery System (CDDS) has emerged during the last decade as a possible drug delivery system against several diseases, which may lead to the creation of a sub-disciple of pharmaceutics to be explored called ‘chronopharmaceutics’. The review addresses the approaches to this sub-discipline, call attention to potential disease-targets, identifies existing technologies, hurdles and future of chropharmaceuticals. Chronopharmaceuticals coupled with nanotechnology could be the future of DDS, and lead to safer and more efficient disease therapy in the future.
Export Options
About this article
Cite this article as:
K. Philip Anil and Philip Betty, Chronopharmaceuticals: Hype or Future of Pharmaceutics, Current Pharmaceutical Design 2011; 17 (15) . https://dx.doi.org/10.2174/138161211796197151
DOI https://dx.doi.org/10.2174/138161211796197151 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Autophagy: For Better or for Worse, in Good Times or in Bad Times …
Current Molecular Medicine Lipoprotein (a) Evolution: Possible Benefits and Harm. Genetic and Non-Genetic Factors Influencing its Plasma Levels
Current Medicinal Chemistry Therapeutic Utilisations of Vasopressin and Oxytocin in Mood Disorders
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Halting Arterial Aging in Patients with Cardiovascular Disease: Hypolipidemic and Antihypertensive Therapy
Current Pharmaceutical Design Cardioprotective Effects of Natural Products <i>via</i> the Nrf2 Signaling Pathway
Current Vascular Pharmacology Adrenomedullins: Therapeutic Potential in Cardiovascular Disease
Current Hypertension Reviews Gender Differences in the Clinical Presentation of Heart Disease
Current Pharmaceutical Design G Protein-Coupled Receptors and their Signaling Pathways: Classical Therapeutical Targets Susceptible to Novel Therapeutic Concepts
Current Pharmaceutical Design Levosimendan: From Basic Science to Clinical Trials
Recent Patents on Cardiovascular Drug Discovery Cellular and Molecular Networks in Chronic Myeloid Leukemia: The Leukemic Stem, Progenitor and Stromal Cell Interplay
Current Drug Targets Utilization of Evidence-Based Secondary Prevention Medications at the Time of Discharge in Patients with Acute Coronary Syndrome (ACS) in Qatar
Current Vascular Pharmacology Editorial (Thematic Issue: Novel Therapeutic Strategies for Cardiovascular Disease Treatment: From Molecular Level to Nanotechnology)
Current Pharmaceutical Design Is It Possible to Apply Secondary Stroke Prevention Guidelines to Very Old Populations?
Cardiovascular & Hematological Disorders-Drug Targets EDITORIAL [Hot Topic-II: PPAR Ligands and Cardiovascular Disorders: Friend or Foe (Guest Editors: Pitchai Balakumar and Gowraganahalli Jagadeesh)]
Current Molecular Pharmacology Hypertension in Obstructive Sleep Apnoea
Vascular Disease Prevention (Discontinued) Adalimumab
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Atrial Fibrillation: Epidemiology and Peculiarities in the Elderly
Cardiovascular & Hematological Agents in Medicinal Chemistry Biofilm Inhibition of Spoilage Bacteria by Argentinean Fruit Juices with Antihypertensive Activity
Current Pharmaceutical Biotechnology A Systematic Approach to Hypertensive Urgencies and Emergencies
Current Hypertension Reviews Update on the Pathophysiological Role of Intracellular Signaling Pathways in Atherosclerotic Plaques and Ischemic Myocardium
Current Signal Transduction Therapy